神经瘤周围水分离治疗急性截肢后疼痛的观察性研究
结果显示水分离组在12周时残肢痛降幅更大,幻肢痛仅在4周内改善,且阿片用量显著下降,但满意度无显著差异。
要点
- 水分离联合阿片类可更大幅度降低12周残肢痛,幻肢痛改善仅维持4周
- 水分离组阿片日用量从41.32±9.63降至33.42±8.78吗啡当量(p=0.001)
- 12周满意度两组无显著差异,需随机对照试验验证
核心结论
- 神经瘤周围水分离可能改善残肢痛,对幻肢痛改善程度较轻,早期实施可能更有利。
- 研究提供初步效应量估计,提示急性疼痛可能是对干预反应更佳的患者特征。
- 需随机对照试验确认结果并控制已识别的混杂变量。
研究设计与样本
- 共同主要结局为12周时平均残肢痛和幻肢痛较基线的中位下降幅度。
主要发现
- 12周时水分离组残肢痛降幅大于单用阿片组(-2.00±1.00 vs -1.00±1.00;p<0.001),更早时间点亦如此。
- 幻肢痛仅在4周内显示改善。
- 12周时水分离组医院焦虑抑郁量表焦虑评分较低(10.00±2.00 vs 11.00±1.00;p<0.001),抑郁评分无差异。
- 水分离组阿片用量从41.32±9.63降至33.42±8.78吗啡当量/天(p=0.001),单用阿片组无显著变化(p=0.20)。
- 12周满意度率差异无统计学意义。
关键数值与推荐
- 复合阳性结局定义为平均残肢痛和幻肢痛下降≥2分或≥30%,治疗满意,且无需增加镇痛药。
- 水分离组残肢痛12周降幅-2.00±1.00,单用阿片组-1.00±1.00(p<0.001)。
- 水分离组焦虑评分10.00±2.00,单用阿片组11.00±1.00(p<0.001)。
- 水分离组阿片用量41.32±9.63降至33.42±8.78吗啡当量/天(p=0.001)。
临床怎么用
- 对战争相关截肢后6个月内伴疼痛性神经瘤患者,可考虑神经瘤周围水分离作为阿片治疗的辅助手段。
- 水分离可能有助于减少残肢痛和阿片用量,但对幻肢痛改善有限且短暂。
- 实施时应关注焦虑评分变化,抑郁评分未见显著改善。
局限性
- 探索性观察性研究,非随机对照,存在混杂变量。
- 满意度差异不显著,幻肢痛改善仅短期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This exploratory study investigates the potential of perineuromal hydrodissection as an adjunct to opioid therapy for postamputation pain, specifically focusing on residual limb and phantom limb pain (PLP). Given the correlations between acute pain and the development of chronic pain, the primary aims were to estimate the effect size of early hydrodissection of scar tissue around residual limb neuroma(s) and to identify the best time frame for treatment. METHODS: Seventy-four patients with war-related limb amputations and painful neuromas were included in this observational analysis. Thirty-eight Ukrainian patients with war-related limb amputation and a painful neuroma(s) who underwent hydrodissection and opioid therapy within 6 months of amputation were compared with 36 patients who received opioids alone. Co-primary outcome measures were median reduction from baseline in average residual limb and PLP at 12 weeks. The composite positive outcome was designated as a ≥2-point decrease or 30% reduction in average residual limb and PLP, satisfaction with treatment, and not requiring an increase in analgesics. RESULTS: Hydrodissection as an add-on to opioids resulted in a greater reduction in average residual limb pain at 12 weeks (-2.00±1.00 vs -1.00±1.00; p<0.001) and earlier time periods, but PLP only through 4 weeks. At 12 weeks, Hospital Anxiety and Depression Scale anxiety (10.00±2.00 vs 11.00±1.00; p<0.001) but not depression score was lower in the hydrodissection group. Opioid use in the hydrodissection group significantly declined from 41.32±9.63 to 33.42±8.78 morphine equivalents per day (p=0.001) over the study, but not in the opioid-only group (p=0.20). Differences in 12-week satisfaction rates were not significant. CONCLUSIONS: This exploratory study suggests perineuromal hydrodissection may improve residual limb pain and to a lesser degree phantom limb pain, particularly when implemented early in the course of postamputation pain. The study provides preliminary effect size estimates and identifies acute pain as a potential characteristic of patients who may respond more favorably to this intervention. Randomized controlled trials are needed to confirm these findings and control for the confounding variables identified.
引用
- Dmytriiev D, Liu W, Barsa M, et al. Perineuromal hydrodissection for acute postamputation pain? An observational study in a time of war. Reg Anesth Pain Med. 2026. PMID: 39971386. doi:10.1136/rapm-2024-106307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。